Evicenter
P&T meetings

Ivonescimab

EGFR-mutated non-small-cell lung cancer

Launch
Not announced
79 sources

Section 6 of 6

References

79 sources

  1. Akeso (opens in a new tab)
  2. Akeso (opens in a new tab)
  3. Akeso (2026) (opens in a new tab)
  4. Al Matairi et al. (2025) (opens in a new tab)
  5. CDC (2026) (opens in a new tab)
  6. Chen et al. (2025) (opens in a new tab)
  7. Cheng et al. (2025) (opens in a new tab)
  8. Chiu et al. (2022) (opens in a new tab)
  9. Dai et al. (2026) (opens in a new tab)
  10. Dhillon (2024) (opens in a new tab)
  11. Fang et al. (2024) (opens in a new tab)
  12. Fang et al. (2025) (opens in a new tab)
  13. FDA (2018) (opens in a new tab)
  14. FDA (2024) (opens in a new tab)
  15. FDA (2025) (opens in a new tab)
  16. Frentzas et al. (2024) (opens in a new tab)
  17. HARMONi-A Study Investigators (2024) (opens in a new tab)
  18. HARMONi-A Study Investigators (2026) (opens in a new tab)
  19. IASLC (2025) (opens in a new tab)
  20. JAMA Research Summary (2026) (opens in a new tab)
  21. Jing et al. (2026) (opens in a new tab)
  22. Le et al. (2026a) (opens in a new tab)
  23. Le et al. (2026b) (opens in a new tab)
  24. Lee et al. (2024) (opens in a new tab)
  25. Leighl et al. (2026) (opens in a new tab)
  26. Liu et al. (2025) (opens in a new tab)
  27. Long et al. (2025) (opens in a new tab)
  28. Malapelle et al. (2025) (opens in a new tab)
  29. MedlinePlus (opens in a new tab)
  30. MedlinePlus (opens in a new tab)
  31. MedlinePlus Genetics (opens in a new tab)
  32. Mo et al. (2025) (opens in a new tab)
  33. Mo et al. (2025) (opens in a new tab)
  34. Mok et al. (2024) (opens in a new tab)
  35. National Cancer Institute (opens in a new tab)
  36. National Cancer Institute (2021) (opens in a new tab)
  37. National Medical Products Administration (2025) (opens in a new tab)
  38. Pan et al. (2025) (opens in a new tab)
  39. Pang et al. (2025) (opens in a new tab)
  40. Passaro et al. (2024) (opens in a new tab)
  41. Passaro et al. (2024) (opens in a new tab)
  42. Patel et al. (2026) (opens in a new tab)
  43. PDQ Adult Treatment Editorial Board (2025) (opens in a new tab)
  44. Peled et al. (2025) (opens in a new tab)
  45. Peled et al. (2025) (opens in a new tab)
  46. Sands et al. (2025) (opens in a new tab)
  47. Summit Therapeutics (opens in a new tab)
  48. Summit Therapeutics (opens in a new tab)
  49. Summit Therapeutics (opens in a new tab)
  50. Summit Therapeutics (opens in a new tab)
  51. Summit Therapeutics (2024) (opens in a new tab)
  52. Summit Therapeutics (2024) (opens in a new tab)
  53. Summit Therapeutics (2025) (opens in a new tab)
  54. Summit Therapeutics (2025) (opens in a new tab)
  55. Summit Therapeutics (2025) (opens in a new tab)
  56. Summit Therapeutics (2025) (opens in a new tab)
  57. Summit Therapeutics (2026) (opens in a new tab)
  58. Summit Therapeutics (2026) (opens in a new tab)
  59. Summit Therapeutics (2026) (opens in a new tab)
  60. Summit Therapeutics (2026) (opens in a new tab)
  61. Summit Therapeutics Form 10-K (2025) (opens in a new tab)
  62. Summit Therapeutics Form 10-Q (2026) (opens in a new tab)
  63. Sun et al. (2026) (opens in a new tab)
  64. Vanderpoel et al. (2023) (opens in a new tab)
  65. Vyas et al. (2026) (opens in a new tab)
  66. Wang et al. (2024) (opens in a new tab)
  67. Wang et al. (2024) (opens in a new tab)
  68. Wang et al. (2025) (opens in a new tab)
  69. Wang et al. (2025) (opens in a new tab)
  70. Waterhouse et al. (2025) (opens in a new tab)
  71. Yang et al. (2024) (opens in a new tab)
  72. Yang et al. (2024) (opens in a new tab)
  73. Yang et al. (2025) (opens in a new tab)
  74. Yang et al. (2026) (opens in a new tab)
  75. Zhang et al. (2025) (opens in a new tab)
  76. Zhao et al. (2023) (opens in a new tab)
  77. Zhong et al. (2025) (opens in a new tab)
  78. Zhou et al. (2026) (opens in a new tab)
  79. Zhu et al. (2026) (opens in a new tab)